Sign In
Buy CNS
$70.20
-1.00 (-1.40%)
At Close: Jun 03, 2026
Corero Network Security and Rocket Fibre Sign Multi-Year Deal to Secure Growth and Launch Real-Time DDoS Protection Services
07:00am, Thursday, 12'th Jun 2025
LONDON , June 12, 2025 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a multi-year agreement with
NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, t
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for May 2025
04:23pm, Monday, 09'th Jun 2025
NEW YORK , June 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.6 billion as of May 31, 2025, an increase of $1.1 billion from asset
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
08:05am, Thursday, 05'th Jun 2025
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire /
Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
06:02pm, Thursday, 22'nd May 2025
NEW YORK , May 22, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources o
Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
05:47pm, Thursday, 22'nd May 2025
NEW YORK , May 22, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of t
Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
05:45pm, Thursday, 22'nd May 2025
NEW YORK , May 22, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the sou
Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
05:43pm, Thursday, 22'nd May 2025
NEW YORK , May 22, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of
Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
05:29pm, Thursday, 22'nd May 2025
NEW YORK , May 22, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the dist
LG CNS showcases AI-Enhanced 'PerfecTwin ERP Edition' in the U.S. at SAP Sapphire 2025
12:00am, Thursday, 22'nd May 2025
Introduces new PerfecTwin ERP Edition with AI capabilities such as real transaction data generation for testing and automated removal of sensitive information Expands collaboration plans with SAP
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy research programs at ASGCT 2025.
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
08:05am, Friday, 16'th May 2025
Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multi
Cohen & Steers and IDR Investment Management Partner to Launch Tactical Listed and Private Real Estate Strategy
09:00am, Wednesday, 14'th May 2025
NEW YORK , May 14, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that the firm, in partnership with IDR Investment Management, LLC ("IDR"), has launched an innovative real est
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
09:35am, Tuesday, 13'th May 2025
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
07:00am, Tuesday, 13'th May 2025
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Manag
